In:
Immunotherapy, Future Medicine Ltd, Vol. 9, No. 1 ( 2017-01), p. 57-70
Abstract:
Dysregulation of the type I interferon (IFN) system is associated with various immunologic diseases, such as systemic lupus erythematosus (SLE). Targeting this dysregulation presents an attractive approach for SLE therapy. Sifalimumab, a fully human immunoglobulin G 1 κ monoclonal antibody that binds to and neutralizes most IFN-α subtypes, has been recently evaluated in a Phase IIb study in patients with moderate to severe SLE. Insights gained from earlier studies were used to inform design of the Phase IIb study, to provide a more comprehensive evaluation of sifalimumab. Sifalimumab demonstrated broad efficacy across composite and organ-specific end points, suggesting that targeting of IFN-α is a promising treatment option for SLE, particularly for those patients whose disease is refractory to current standard of care.
Type of Medium:
Online Resource
ISSN:
1750-743X
,
1750-7448
DOI:
10.2217/imt-2016-0090
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2017